Lost money in Beta Bionics, Inc. stock? You may be able to recover your losses.
Holtzman v. Beta Bionics, Inc., No. 8:26-cv-02612-ADS (C.D. Cal.)
A federal securities class action has been filed on behalf of Beta Bionics, Inc. (BBNX) investors. Find out in about 30 seconds whether you may be eligible to participate, at no cost.
- No cost to participate
- No fee unless investors recover
- Talk to a real person, not a call center
- Lead plaintiff deadline
- November 3, 2026
- 32 days remaining
- Class period
- Jul 30, 2025 – Feb 24, 2026
- Eligible purchases fall between these dates
What happened to BBNX
About this case
According to the complaint, Beta Bionics and certain of its executives misled investors about the safety of the company's sole commercial product, the iLet Bionic Pancreas automated insulin pump. The complaint alleges that after receiving an FDA Form 483 in mid-2025 that documented more than 18,000 unreported customer complaints across fewer than 30,000 iLet users — including hundreds of life-threatening hypoglycemic events — the company repeatedly told investors the FDA's concerns were "a very benign issue" limited to how complaints were categorized and had "nothing to do with the actual complaints being received or the number of them," while continuing to tout the device's clinical outcomes. The truth allegedly emerged through a series of disclosures beginning January 8, 2026, when a miss on new patient starts sent the stock down roughly 37% in a single day, followed by investigative reports and the company's January 30, 2026 disclosure of an FDA warning letter, and culminating on February 24, 2026, when the FDA publicly released its warning letter directly contradicting management's characterization. The complaint alleges the stock fell from $31.99 to under $13 per share over this period. Investors who purchased Beta Bionics common stock between July 30, 2025 and February 24, 2026 may have legal rights.
The allegations, in plain terms
- Mid-2025Per the complaint, Beta Bionics received an FDA Form 483 documenting more than 18,000 unreported customer complaints among fewer than 30,000 users of its iLet insulin pump, including hundreds of life-threatening hypoglycemic events.
- July 30, 2025 – class periodDuring the class period, the complaint alleges, executives told investors the FDA's concerns were 'a very benign issue' about how complaints were categorized — with 'nothing to do with the actual complaints being received or the number of them' — while continuing to promote the device's clinical results.
- January 8–9, 2026The company allegedly reported a miss on new patient starts, and the stock fell roughly 37% in a single day, per the complaint — the first in a series of disclosures.
- January 30, 2026The company disclosed it had received an FDA warning letter, following investigative reports, according to the complaint.
- February 24, 2026The FDA publicly released its warning letter, which the complaint alleges directly contradicted management's earlier characterization. Over this period the stock allegedly fell from $31.99 to under $13 per share.
Summarizes allegations in the complaint — they are not findings of any court.
We screen hundreds of stock drops every year and file only a handful. If we're investigating this one, it's because we believe in it.
Block & Leviton is run by the partners whose names are on the door — and our clients deal with them directly, whatever the size of the loss. That's the point of staying small.
A dismissed case turned into a $150 million record.* A recovery from a company that went bankrupt. We build cases to go the distance — not to settle cheap.
* Subject to court approval. Prior results do not guarantee a similar outcome.
Who we are — and why we're involved
Block & Leviton represents investors. We never represent the companies we investigate. When a company's own disclosures reveal that shareholders were misled, we investigate and bring claims to recover those losses.
Our clients are people like you: individual investors, retirees, and pension funds harmed when the truth comes out and a stock falls. There is no cost to you to participate, and attorneys' fees are paid only out of a recovery approved by the court.
Who you'll be dealing with
Jeffrey Block
Represents investors in securities class actions nationwide.
Your first call will usually be with David White, our investor liaison — and our partners are directly involved in every case.
A record courts have trusted
NextEra Energy — $150 million
The district court dismissed the case. We appealed — and won a unanimous reversal in the Eleventh Circuit Court of Appeals. The result: a $150 million settlement — the largest securities class action settlement in the Southern District of Florida in more than 30 years.*
Dismissed — then revived when we persuaded the court to reconsider its own judgment. Settled in 2026.
Recovered for investors even after Tricida itself went bankrupt.
Federal courts have appointed Block & Leviton lead counsel in securities class actions on behalf of investors nationwide. Our attorneys have recovered billions of dollars for investors, retirees, and pension funds.
* Subject to court approval. Prior results do not guarantee a similar outcome. Attorney advertising.
Common questions
Will this cost me anything?
No. There is no cost to submit your information, no cost to participate, and no out-of-pocket cost ever. If there's a recovery, attorneys' fees are paid from it and must be approved by the court.
I'm already part of the class automatically — so why submit my information?
It's true: if you bought BBNX during the class period, you're a class member whether or not you contact anyone. Submitting your information lets us evaluate your specific losses, keep you informed as the case develops, and tell you whether you may benefit from a larger role in the case.
What is a lead plaintiff?
The lead plaintiff is an investor the court appoints to represent the class, typically someone with a significant loss. Lead plaintiffs oversee the litigation on behalf of everyone and are entitled to seek reimbursement for their time. The deadline to seek appointment in this case is November 3, 2026.
I sold my shares after the drop — am I still eligible?
Possibly, yes. What generally matters is that you purchased shares during the class period and were harmed by the decline. Whether you still hold shares today doesn't necessarily disqualify you — submit your details and we'll evaluate your situation.
Does submitting this form make you my lawyers?
No — and that's a protection for you. Submitting the form only lets us evaluate your potential claim, at no cost. If we determine we can help and you decide to move forward, we'll send you a written retainer agreement that spells out the relationship, the contingency fee, and your rights. You're never committed to anything until you've read and signed it.
What happens after I submit the form?
Our team reviews your submission — usually within one business day. David, our investor liaison, will reach out by phone or email, and our partners are directly involved in every case. You're never obligated to do anything.
Attorney advertising. Prior results do not guarantee a similar outcome. Block & Leviton LLP is responsible for the content of this page. Submitting information through this page does not create an attorney-client relationship.